| Status: AWMSG assessment in progress | |
Neoadjuvant/adjuvant androgen deprivation therapy (ADT) to external beam radiotherapy in patients with localised intermediate-risk prostate cancer (off-label). |
|
Medicine details |
|
| Medicine name | relugolix |
| Formulation | 120 mg oral tablets |
| Reference number | OW40 |
| Indication | As above |
| Company | various |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | One Wales |
| Status | AWMSG assessment in progress |
| Scrutiny Panel meeting date | 06/08/2026 |
| OWMAG meeting date | 15/02/2027 |
| AWMSG meeting date | 17/03/2027 |